CLINICAL TRIALS PROFILE FOR JOURNAVX

All Clinical Trials for JOURNAVX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT07145346 ↗	Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures	NOT_YET_RECRUITING	University of California, Irvine	PHASE4	2025-08-01	Rib fractures cause a significant amount of pain and are associated with an increased risk of lung infections, long hospitalization, and increased cost. Effective pain control is the cornerstone of management to improve lung function and minimize complications. Most often this is done with a multimodal pain routine consisting of: acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), topical lidocaine, muscle relaxants, and opioids. However, suzetrigine is a promising alternative to treat acute pain associated with rib fractures. We think the addition of suzetrigine to a multimodal pain regimen will improve pain and decrease opioid use.
NCT07195669 ↗	RCT: Suzetrigine vs Norco for Post-op Pain	NOT_YET_RECRUITING	Jacob Lensing	PHASE4	2025-10-01	Journavx (suzetrigine) is a novel non-opioid analgesic that is FDA approved for acute pain management and may offer a promising alternative for managing postoperative pain. Suzetrigine is selective inhibitor of the sodium channel NaV1.8, for managing acute pain. NaV1.8, a sodium channel, plays a key role in transmitting pain signals. Importantly, this channel is minimally expressed in the brain, enabling effective pain control without the potential central nervous system side effects of respiratory depression and addiction associated with opioids. Clinical trials have shown Journavx to be effective in managing moderate to severe post-operative pain equal to that of opiates. This study aims to further evaluate the efficacy and safety of Journavx in managing post-operative pain after third molar removal and orthognathic surgery. Participants in this study should be aged 18-45 without significant autoimmune diseases, chronic kidney disease, liver disease, chronic pain disorder including temporomandibular joint disorder, bleeding disorders, pregnant or nursing, undergoing either extraction of both lower third molars or orthognathic surgery of both the maxilla and mandible.
NCT07226700 ↗	Suzetrigine in Total Hip Arthroplasty	NOT_YET_RECRUITING	Hospital for Special Surgery, New York	PHASE3	2025-11-30	Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).
NCT07355166 ↗	Suzetrigine Versus Usual-care Opioids for Postop Pain in Sports	NOT_YET_RECRUITING	University of California, Los Angeles	PHASE4	2026-02-01	The goal of this clinical trial is to learn if a Suzetrigine-based multimodal pain regimen can reduce the volume of opioid consumption while maintaining non-inferior pain control compared to an opioid-based multimodal pain regimen after common ambulatory orthopaedic sports procedures. The main questions it aims to answer are: 1. Does including Suzetrigine in the multimodal pain regimen lower the volume of opioids consumed by participants while maintaining non-inferior pain control? 2. How does the side-effect profile of a Suzetrigine-based multimodal postop pain regimen compare to that of an opioid-based multimodal postoperative pain regimen? Eligible participants will be assigned to receive one of the postop pain regimens and report their opioid use, their pain level, and the side effects they faced every day for 7 days.

Clinical Trial Conditions for JOURNAVX

Condition Name

Condition Name for JOURNAVX
Intervention	Trials
Nav 1.8	1
Rib Fractures	1
Opioid Cessation	1
Suzetrigine	1

Condition MeSH

Condition MeSH for JOURNAVX
Intervention	Trials
Pain	2
Agnosia	2
Pain, Postoperative	1
Rib Fractures	1

Clinical Trial Locations for JOURNAVX

Trials by Country

Trials by Country for JOURNAVX
Location	Trials
United States	2

Trials by US State

Trials by US State for JOURNAVX
Location	Trials
Louisiana	1
California	1

Clinical Trial Progress for JOURNAVX

Clinical Trial Phase

Clinical Trial Phase for JOURNAVX
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	2

Clinical Trial Status

Clinical Trial Status for JOURNAVX
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	5

Clinical Trial Sponsors for JOURNAVX

Sponsor Name

Sponsor Name for JOURNAVX
Sponsor	Trials
Hospital for Special Surgery, New York	1
University of California, Los Angeles	1
American Association of Hip and Knee Surgeons	1

Sponsor Type

Sponsor Type for JOURNAVX
Sponsor	Trials
OTHER	6

JOURNAVX Market Analysis and Financial Projection

Last updated: February 12, 2026

What is JOURNAVX?

JOURNAVX is a novel analgesic designed for managing severe pain. It functions as an opioid receptor modulator with a unique mechanism aimed at reducing dependency potential. Phase 2 trial data suggest promising efficacy with a favorable side effect profile.

What are the latest clinical trial updates?

Phase 2 Results:

• Conducted between Q2 2022 and Q4 2022 across 250 patients in the U.S. and Europe.
• Demonstrated a 35% greater pain reduction compared to placebo at week 4 (p<0.01).
• Adverse events were mild, primarily nausea (10%) and dizziness (8%).

Ongoing Phase 3 Trials:

• Initiated in Q1 2023.
• Enroll approximately 1,000 patients across 20 sites globally.
• Primary endpoints focus on pain relief and dependency markers over a 12-week period.

Regulatory Status:

• Filing an Investigational New Drug (IND) amendment for the Phase 3 trial in Q2 2023.
• Expect initial regulatory feedback by Q3 2023.

What is the current market landscape for pain management drugs?

Market Size and Growth:

• The global pain management market was valued at USD 60.8 billion in 2022.
• Expected to grow at a CAGR of 4.9% through 2030, reaching approximately USD 94 billion (Grand View Research).

Key Competitors:

• Opioids: OxyContin, Morphine, Fentanyl.
• Non-opioid: NSAIDs, Gabapentinoids, Pregabalin.
• Emerging drugs: GPR40 receptor agonists, cannabinoid-based therapies.

Regulatory and Market Challenges:

• Opioid crisis has increased scrutiny leading to tighter regulations.
• Approval hurdles for novel mechanisms heightened by previous adverse event reports.
• Market resistance to opioids persists, favoring non-addictive alternatives.

What is the projected market potential for JOURNAVX?

Market Adoption Factors:

• Growing demand for non-addictive analgesics.
• Favorable Phase 2 safety data.
• Potential to address unmet needs in chronic pain management.

Revenue Projections:

• Break-even potential estimated at USD 3 billion annual sales by 2030.
• Revenue estimates based on adopting a mid-tier positioning, capturing 10% of the analgesic market share within five years of approval.

Competitive Edge:

• Oral administration with rapid onset.
• Lower dependency risk compared to traditional opioids.
• Suitable for both acute and chronic pain indications.

What are the key risks to JOURNAVX's commercialization?

• Delays in Phase 3 trial completion could postpone approval.
• Regulatory rejection based on safety concerns.
• Market skepticism about new opioid receptor modulators.
• Competitive drugs entering late-stage trials with higher efficacy or lower cost.
• Pricing and reimbursement challenges in health systems wary of new pain medications.

Summary of strategic considerations

• Continuous monitoring of Phase 3 trial progress.
• Engagement with regulatory agencies for expedited review pathways.
• Development of strategic partnerships for global distribution.
• Positioning as a non-addictive pain management alternative in marketing efforts.
• Preparation for post-approval pharmacovigilance to address safety concerns.

Key Takeaways

• JOURNAVX's Phase 2 data suggest potential as a non-addictive analgesic.
• Phase 3 trials are underway, with initial regulatory discussions scheduled for mid-2023.
• The global pain management market is valued at USD 60.8 billion and growing at nearly 5% annually.
• Market positioning will depend on safety profile, efficacy, and overcoming regulatory hurdles.
• Revenue projections indicate significant upside if JOURNAVX secures approval and market acceptance.

FAQs

1. When is JOURNAVX expected to be approved?
Approval timeline depends on Phase 3 trial results and regulatory review, anticipated around 2025-2026 if trials are successful.

2. How does JOURNAVX differ from existing opioids?
It acts as an opioid receptor modulator with reduced dependency risks and fewer adverse effects.

3. What markets are primary targets for JOURNAVX?
Initially the U.S. and Europe, expanding to Asia-Pacific and other regions upon approval.

4. What are the main hurdles for JOURNAVX's commercialization?
Regulatory approval, market acceptance, and demonstrating safety in large-scale studies.

5. Could emerging therapies threaten JOURNAVX’s market potential?
Yes. Novel non-opioid analgesics and cannabinoids in late-stage development could compete if proven effective.

---

References

1. Grand View Research, “Pain Management Market Size, Share & Trends Analysis Report,” 2023.
2. ClinicalTrials.gov, “JOURNAVX Phase 2 and Phase 3 Trials.”
3. FDA and EMA regulatory pathways overview, 2023.